

Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



Contents lists available at ScienceDirect

Tetrahedron Letters

journal homepage: www.elsevier.com/locate/tetlet

Conjugate addition of amines to chiral 3-aziridin-2-yl-acrylates

Doo-Ha Yoon^a, Hyun-Joon Ha^{a,*}, Bong Chan Kim^b, Won Koo Lee^{b,*}^a Department of Chemistry and Protein Research Centre for Bio-Industry, Hankuk University of Foreign Studies, Yongin 449-719, Republic of Korea^b Department of Chemistry, Sogang University, Seoul 121-742, Republic of Korea

ARTICLE INFO

Article history:

Received 28 December 2009

Revised 11 February 2010

Accepted 16 February 2010

Available online 19 February 2010

Dedicated with respect to the memory of Professor Chi Sun Hahn

Keywords:

Conjugate addition

Amine

Aziridin-2-yl-acrylates

Diamine

ABSTRACT

Conjugate addition of benzylamine to chiral methyl *cis*-3-aziridin-2-yl-acrylates was successfully proceeded to yield 3-aziridin-2-yl-3-benzylaminopropionates in high yield with high stereoselectivity. The addition products were used for the asymmetric synthesis of vicinal diamine derivatives including 4-amino-5-methylpyrrolidin-2-one, 3,4-diaminopentanoate, and 5-chloromethyl-4-alkoxycarbonylmethylimidazolidin-2-one.

© 2010 Elsevier Ltd. All rights reserved.

Synthesis of stereochemically well-defined 1,2-diamines is still a great challenge to many organic chemists due to their vast utilities as catalysts, metal-ligands, and sub-unit of some natural products.¹ Especially β,γ -diamino acids and their cyclic forms like 4-aminopyrrolidin-2-one and imidazolidin-2-one have unique properties as peptidomimetics² and as constituents of biologically active molecules including renin-inhibitory statin analogs,³ anti-fungal and cytotoxic microsclerodermins,⁴ and antipsychotic nemonapride.⁵ Furthermore, the reduced form of 4-aminopyrrolidin-2-one provides an entry into the 3-aminopyrrolidine family of alkaloids (Fig. 1).⁶

Considering the vast utilities of these compounds, limited methods are available and most of which is based on α -amino acids as starting material through homologations followed by introducing one more amine functionality.⁷ These known methods were suffered from the limited sources of starting substrates and the multi-reaction steps including low yield. In this Letter is described a general and facile synthetic method to access enantiomerically pure anti β,γ -diamino acids and their cyclic forms using chiral aziridine.

During last several years we have shown that enantiomerically pure aziridine-2-carboxylate is a configurationally stable surrogate of α - or β -amino acids.⁸ Homologation and proper functionalization of carboxylate followed by aziridine ring opening provided




Figure 1. β,γ -Diamino acids, 4-aminopyrrolidin-2-ones, and imidazolidine-2-ones.


many valuable compounds such as unnatural amino acids,⁹ sphinganine,¹⁰ phytosphingosine,¹¹ ceramide analogs,¹² and terminal 1,2-diamines.¹³ Homologation by two carbons and introduction of one more amino group adjacent to the aziridine-ring will be able to provide a good synthetic intermediate toward the targeted β,γ -diamino acids and their cyclic forms.

At first *trans*- and *cis*-3-[(1*R*)-phenylethylaziridine]-(2*R*)- and (2*S*)-yl]-acrylates were selectively prepared from aziridine-2-carboxaldehyde.⁸ The reaction of [(1*R*)-phenylethylaziridine]-(2*R*)-carboxaldehyde with (EtO)₂POCH₂CO₂R yielded *trans*-3-[(1*R*)-phenylethylaziridin]-(2*S*)-yl]-acrylate in more than 95% yield with the ratio of 98:2 regardless of R (methyl and ethyl). The same reaction with Ph₃PCH₂CO₂R leading to alkyl *cis*-3-[(1*R*)-phenylethylaziridin]-(2*R*)- and (2*S*)-yl]-acrylates, **1** and **2**, was also successfully provided in more than 93% yield with the ratio of 88:12 (R = Me) and 86:14 (R = Et). Interestingly, only the *cis* and *trans* isomers bearing methyl ester were chromatographically

* Corresponding authors. Tel.: +82 31 3304369; fax: +82 31 3304566 (H.-J.H.); tel.: +82 2 7058449; fax: +82 2 7010967 (W.K.L.).

E-mail addresses: hjha@hufs.ac.kr (H.-J. Ha), wonkoo@sogang.ac.kr (W.K. Lee).

Table 1
Addition of benzylamines to methyl *cis*-3-[(1*R*)-phenylethylaziridin]-(2*R*)-yl]-acrylate (**1**)




Entry	RNH ₂	Temp (°C)	Time ^a (h)	Yield ^b (%)	Ratio ^c (3A : 3B)
1	PhCH ₂ NH ₂ (a)	rt	14	95	2.9:1
2	PhCH ₂ NH ₂ (a)	0	24	91	2.9:1
3	PhCH ₂ NH ₂ (a)	-40	20	98	4.0:1
4	(<i>R</i>)-Ph(CH ₃)CHNH ₂ (b)	50	7	95	3.3:1
5	(<i>S</i>)-Ph(CH ₃)CHNH ₂ (c)	50	7	97	>99:1

^a The reaction was carried out with amine in MeOH.

^b Yields, not optimized.

^c Ratios, determined by ¹H NMR.




Scheme 1. Reagents and conditions: (i) (1) NaH, Cl₃COCOCCl₃, -10 °C, THF, 3 h.

separable (*R_f* values, 0.75 and 0.70 for *cis* and *trans*, hexane/EtOAc, 1:1 (v/v)).

Conjugate addition of benzylamine (**a**) to methyl *trans*- and *cis*-3-[(1*R*)-phenylethylaziridin]-(2*R*)-yl]-acrylate in MeOH showed the big difference on the reactivity and stereoselectivity between two substrates. The *cis* isomer **1** is much more reactive to yield the expected diastereomeric mixture **3Aa** and **3Ba** in a 2.9:1 ratio at room temperature while *trans* is quite sluggish with no selectivity (Table 1, entry 1) The ratio obtained of **3Aa** was changed by lowering the reaction temperature to 0 °C and -45 °C as 2.9:1 and 4.0:1, respectively (Table 1, entries 2 and 3). Addition of chiral amines for the possible improvement of diastereoselectivity was succeeded with (*R*)- and (*S*)- α -methylbenzylamine (**b** and **c**) to yield addition products. In case of (*R*)- α -methylbenzylamine (**b**) not much improvement was observed in terms of selectivity to give 3.3:1 (**3Ab**:**3Bb**) (entry 4). However, the addition of (*S*)- α -methylbenzylamine (**c**) yielded a single isomer **3Ac** as a sole product judged by NMR and HPLC analyses (entry 5). This high selectivity arisen from the right match between 2*R* configuration

Table 2
Addition of benzylamines to methyl *cis*-3-[(1*R*)-phenylethylaziridin]-(2*S*)-yl]-acrylate (**2**)



Entry	RNH ₂	Temp (°C)	Time ^a (h)	Yield ^b (%)	Ratio ^c (4A : 4B)
1	PhCH ₂ NH ₂ (a)	rt	14	96	2.3:1
2	PhCH ₂ NH ₂ (a)	0	24	91	2.3:1
3	PhCH ₂ NH ₂ (a)	-40	30	95	2.6:1
4	(<i>R</i>)-Ph(CH ₃)CHNH ₂ (b)	50	8	82	1.2:1
5	(<i>S</i>)-Ph(CH ₃)CHNH ₂ (c)	50	8	95	2.1:1

^a The reaction was carried out with amine in MeOH.

^b Yields, not optimized.

^c Ratios, determined by ¹H NMR.

of the phenylethyl group of the aziridine ring and (*S*)- α -methylbenzylamine nucleophile.

The inseparable diastereomeric mixture of **3Aa** and **3Ba** obtained from entry 2 in Table 1 was further reacted with triphosgene and NaH to yield 4-chloromethyl-5-methoxycarbonylmethylimidazolidin-2-ones **5** and **6** (Scheme 1).¹⁴

The coupling constants of two vicinal hydrogens at C4 and C5 of compounds **5** (major) and **6** (minor) were 7.5 and 3.0 Hz, respectively. On the basis of these values we could determine the stereochemistry of **3Aa** and **3Ba** as *erythro* and *threo*, respectively.^{14,15}

A similar selectivity was observed with methyl *cis*-3-[(1*R*)-phenylethylaziridin]-(2*S*)-yl]-acrylate (**2**) as the starting substrate and benzylamine (**a**) to give a *erythro* (**4Aa**) and *threo* (**4Ba**) mixture with the ratio as 2.3:1 and 2.6:1 (entries 1–3 of Table 2). Both the chiral nucleophiles (*R*)- α -methylbenzylamine (**b**) and (*S*)- α -methylbenzylamine (**c**) with **2** yielded addition products with poor selectivities as 1.2:1 and 2.1:1, respectively (entries 4 and 5 of Table 2).

The drastic difference in the stereoselectivity was observed during the addition reaction of the chiral nucleophiles (*R*)- α -methylbenzylamine (**b**) and (*S*)- α -methylbenzylamine (**c**) to either **1** or **2** (entries 4 and 5 in Table 1 and Table 2). This implies the participation of the α -methylbenzyl group at the ring nitrogen and the coming nucleophile resulted the 'matched' (entry 5 in Table 1) and 'mismatched' cases (entry 4 in Table 1, and entries 4 and 5 in Table 2) in the transition state during the course of the reaction.¹⁶

The possible transition state stems from the most stable conformer of 2-substituted aziridine with two substituents X and Y





Figure 2. (a), (b) Front and side views of the aziridine with two substituents X and Y at N1 and C2. (c) View of methyl *cis*-3-[(1'*R*)-phenylethylaziridin]-(2*R*)-yl]-acrylate (**1**) and the possible approaching faces of the amine nucleophile in the transition state model.



Scheme 2. Reagents and conditions: (i) (1) H_2 (1 atm), $Pd(OH)_2$, rt, 4 h, (2) $(Boc)_2O$, MeOH, rt, two steps 89%. (ii) LiOH, EtOH/ H_2O = 5:1 (v/v) 50 °C, 8 h, rt, ion-exchange column, 82%.

situated in *trans*-relationships as shown in Figure 2 (a) and (b). This *trans*-relationship was also observed in many crystalline structures of aziridines.¹⁷ Putting both substituents of phenylethyl (X) and methoxycarbonyl (Y) groups generates the structure (c) in Figure 2 with possible two faces, *re* and *si*, for the nucleophile to come.

Among two possible directions *re* face attack is more favorable rather than *si* face away from the steric hindrance, which is the controlling factor to yield the *erythro* adduct as the major product along with the additional stereodifferentiation by (*R*)- α -methylbenzylamine. This stereochemical pathway is opposite to the reaction with chelation-controlled transition state to yield the *threo* product.¹⁴

The addition product **3Ac** was further treated with an atmospheric pressure of hydrogen in the presence of $Pd(OH)_2$ catalyst followed by reaction with $(Boc)_2O$ to yield (4*R*,5*S*)-4-*t*-butyloxycarbonylamino-5-methylpyrrolidin-2-one (**7**) in a 89% yield. Hydrolysis of **7** followed by anion exchange column afforded the known (3*R*,4*S*)-4-amino-3-*t*-butyloxycarbonylamino-pentanoic acid (**8**) in a 82% yield (Scheme 2).¹⁸ The addition product **3Ac** will be served as a synthetic intermediate for the preparation of various chiral diamines through aziridine ring opening with various nucleophiles.⁸

In conclusion, the conjugate addition of benzylamine to chiral methyl *cis*-3-[(1'*R*)-phenylethylaziridin]-(2*R*)- and (2*S*)-yl]-acrylates provides the *erythro* adduct, 3-(aziridin-2-yl)-3-benzylamino-propionate as the major product. Additional stereodifferentiation by (*S*)- α -methylbenzylamine to the substrate (2*R*)-acrylates yielded a single enantiomeric adduct in high yield which was used as the precursor for the substituted nitrogen-containing heterocycles and enantiomerically pure β,γ -diaminoacids.

Acknowledgments

This work was supported by the Hufs Grant (2010) and Korea Science and Engineering Foundation (R01-2007-000-20037-0 for H.-J.H and KRF-2008-C00481 and NRF-2009-0081956 for W.K.L.).

Supplementary data

Supplementary data (experimental procedures and characterization data for all new compounds) associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2010.02.087.

References and notes

- For reviews on the chemistry of 1,2-diamines, see: (a) Kotti, S. R. S. S.; Timmons, C.; Li, G. *Chem. Biol. Drug. Design.* **2006**, *67*, 101; (b) Fache, F.; Schulz, E.; Tommasino, M. L.; Lemaire, M. *Chem. Rev.* **2000**, *100*, 2159; (c) Lucet, D.; Le Gall, T.; Mioskowski, C. *Angew. Chem., Int. Ed.* **1998**, *37*, 2580.
- (a) Hoang, C. T.; Alezra, V.; Guillot, R.; Kouklovsky, C. *Org. Lett.* **2007**, *9*, 2521; (b) Lehmann, T.; Michel, D.; Glänzel, M.; Waibel, R.; Gmeiner, P. *Heterocycles* **1999**, *51*, 1389.
- Jones, D. M.; Sueiras-Diaz, J.; Szelke, M.; Leckie, B. J.; Beattie, S. R.; Morton, J.; Neidle, S.; Kuroda, R. *J. Pept. Res.* **1997**, *50*, 109.
- (a) Skropeta, D. *Nat. Prod. Rep.* **2008**, *25*, 1131; (b) Hoang, C. T.; Nguyen, V. H.; Alezra, V.; Kouklovsky, C. *J. Org. Chem.* **2008**, *73*, 1162; (c) Bewley, C. A.; Debitus, C.; Faulkner, D. *J. Am. Chem. Soc.* **1994**, *116*, 7631.
- Iwanami, S.; Takashima, M.; Hirata, Y.; Hasegawa, O.; Usuda, S. *J. Med. Chem.* **1981**, *24*, 1224.
- For more recent examples, see: (a) Jin, J.; An, M.; Sapienza, A.; Aiyar, N.; Naselsky, D.; Sarau, H. M.; Foley, J. J.; Salyers, K. L.; Knight, S. D.; Keenan, R. M.; Rivero, R. A.; Dhanak, D.; Douglas, S. A. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3950; (b) Fish, P. V.; Barta, N. S.; Gray, D. L. F.; Ryckmans, T.; Stobie, A.; Wakenhut, F.; Whitlock, G. A. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4355; (c) Wakenhut, F.; Fish, P. V.; Fray, M. J.; Gurrell, I.; Mills, J. E.; Stobie, A.; Whitlock, G. A. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4308.
- (a) Pinheiro, S.; da Silva Júnior, R. C.; de Souza, A. S.; de M Carneiro, J. W.; Muri, E. M. F.; Antunes, O. A. C. *Tetrahedron. Lett.* **2009**, *50*, 2402; (b) Hoang, C. T.; Bouillere, F.; Johannesen, S.; Zulauf, A.; Panel, C.; Pouillhes, A.; Gori, D.; Alezra, V.; Kouklovsky, C. *J. Org. Chem.* **2009**, *74*, 4177. and references cited therein.
- Lee, W.-K.; Ha, H.-J. *Aldrichimica Acta* **2003**, *36*, 57. and references cited therein.
- Park, C. S.; Choi, H. G.; Lee, H.; Lee, W. K.; Ha, H.-J. *Tetrahedron: Asymmetry* **2000**, *11*, 3283.
- Yun, J. M.; Sim, T. B.; Hahm, H. S.; Lee, W. K.; Ha, H.-J. *J. Org. Chem.* **2003**, *68*, 7675.
- Yoon, H. J.; Kim, Y.-W.; Lee, B. K.; Lee, W. K.; Kim, Y.; Ha, H.-J. *Chem. Commun.* **2007**, 79.
- Ha, H.-J.; Hong, M. C.; Ko, S. W.; Kim, Y. W.; Lee, W. K.; Park, J. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1880.
- Lee, B. K.; Kim, M. S.; Hahm, H. S.; Kim, D. S.; Lee, W. K.; Ha, H.-J. *Tetrahedron* **2006**, *62*, 8393.
- Suh, M.-J.; Kim, S. W.; Beak, S. I.; Ha, H.-J.; Lee, W.-K. *Synlett* **2004**, 489.
- (a) Pelletier, S. M.-C.; Ray, P. C.; Dixon, D. *J. Org. Lett.* **2009**, *11*, 4512; (b) Park, C. S.; Kim, M. S.; Sim, T. B.; Pyun, D. K.; Lee, C. H.; Choi, D.; Lee, W. K.; Chang, J.-W.; Ha, H.-J. *J. Org. Chem.* **2003**, *68*, 43.
- In our early work we observed that the configuration of (α)-methylbenzyl group at N1 of aziridine affected drastically the reactivity on the substitution reaction of 2-sulfonyloxymethylaziridines. Han, S.-M.; Ma, S.-h.; Ha, H.-J.; Lee, W. K. *Tetrahedron* **2008**, *64*, 11110.
- (a) Lee, K.-D.; Suh, J.-M.; Park, J.-H.; Ha, H.-J.; Choi, W. G.; Park, C. S.; Chang, J. W.; Lee, W. K.; Dong, Y.; Yun, H. *Tetrahedron* **2001**, *57*, 8267; (b) Dong, Y.; Yun, H.; Park, C. S.; Lee, W.-K.; Ha, H.-J. *Acta Crystallogr., Sect. C* **2003**, *59*, 659.
- Kano, S.; Yokomatsu, T.; Iwasawa, H.; Shibuya, S. *Chem. Pharm. Bull.* **1988**, *36*, 3341.